Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Malignancies × pemigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cholangiocarcinoma 3 Neoplasm Metastasis 2 Carcinoma, Transitional Cell 2 Acrocephalosyndactylia 2 Oligodendroglioma 1 Glioma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Advanced Malignancies 1

Interventions

tanespimycin 1 pemigatinib 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated

10 enrolled 9 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡